scholarly journals High Rate of Sexual Dysfunction Following Surgery for Rectal Cancer

2014 ◽  
Vol 30 (5) ◽  
pp. 210 ◽  
Author(s):  
Wafi Attaallah ◽  
Caglar Ertekin ◽  
Ilker Tinay ◽  
Cumhur Yegen
Keyword(s):  
Rectal Cancer ◽  
Sexual Dysfunction ◽  
High Rate

Paternity, relationship, sexual activity and fertility in testicular cancer (TC) survivors (TCS): Results from a single institution observational prospective study.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 380-380
Author(s):  
Davide Bimbatti ◽  
Francesco Pierantoni ◽  
Marco Maruzzo ◽  
Filippo Maria Deppieri ◽  
Aichi Msaki ◽  
...  
Keyword(s):  
Sexual Dysfunction ◽  
Premature Ejaculation ◽  
Relative Survival ◽  
High Dose Chemotherapy ◽  
High Rate ◽  
Interdisciplinary Management ◽  
High Dose ◽  
Family Status ◽  
Set Up ◽  
Status Data

380 Background: TC represents 1% of male neoplasms but it is the most common in young adults. Interdisciplinary management with chemotherapy, radiotherapy and surgery has led to a 10-year relative survival rate of up to 95%. These treatments (Tx) have short- and long-term side effects. While sexual dysfunction can reduce fertility, psychosocial distress can create relationship problems and finally affect the ability to procreate. Methods: From February 2020, we submitted a series of questionnaires to all the patients (pts) currently followed-up at the Istituto Oncologico Veneto free from TC recurrence for at least 2 years from the last Tx. International Index of Erectile Function (IIEF-15) and Premature Ejaculation Diagnostic Tool (PEDT) were used. We also set up a questionnaire to investigate paternity and family status. Data about disease and treatments were collected from medical records. Results: 84 TCS completed the questionnaires, clinical data are reported in the table below. 29,8% of pts fathered children before diagnosis with a strong correlation with older age at diagnosis (45,4 vs 30,8 years, p<0,001). After Tx, 14 pts had children: 9 of which naturally, 2 out 6 were successful via assisted reproductive technology (ART) (including one patient that received high-dose chemotherapy and stem cell transplantation), 3 via adoption. 89,3% of pts had stable relationships. Of pts who did not have children: 13,1% claimed to be due to lack of a partner, 39,3% claimed to be unready, while 14,3% had tried unsuccessfully to conceive. While 28,6% pts claim to currently have fertility issues, only 8,3% of pts reported to have these issues before diagnosis. 70,2% of pts performed a spermiogram after Tx, 10 pts had spermatogenic impairment. Higher rate of sexual dysfunction after Tx was detected by questionnaires while only 4 pts claimed to have had a pre-existing issue prior to TC diagnosis. PEDT shows that 38,1% had premature ejaculation and that in 22,6% this issue is highly probable. IIEF confirms a high rate of erectile dysfunction (14,3% severe and 10,7% mild or moderate). No correlations were identified between sexual dysfuntion and previous Tx. Conclusions: Most TCS had not planned fatherhood while 16,7% had children after Tx and 14.3% tried unsuccessfully to conceive. ART and adoption is possible but challenging and little used. PEDT and IIEF found high rates of sexual dysfunction but no association with previous Tx were found. [Table: see text]

scholarly journals P-133 Assessment of sexual dysfunction in rectal cancer survivors

2016 ◽  
Vol 27 ◽  
pp. ii39
Author(s):  
J. Rodrigues ◽  
R. Soares ◽  
N. Bonito ◽  
M. Marques ◽  
P. Jacinto ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Sexual Dysfunction ◽  
Cancer Survivors

CCTG CO.28 primary endpoint analysis: Neoadjuvant chemotherapy, excision and observation for early rectal cancer, the NEO trial.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 3508-3508
Author(s):  
Hagen Fritz Kennecke ◽  
Carl J Brown ◽  
Jonathan M. Loree ◽  
Husein Moloo ◽  
Derek J. Jonker ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
High Risk ◽  
Tumor Progression ◽  
Primary Endpoint ◽  
Organ Preservation ◽  
Rectal Adenocarcinoma ◽  
The United States ◽  
High Rate ◽  
Pelvic Mri ◽  
Preservation Rate

3508 Background: CO.28 (NCT03259035) is a phase II study designed to determine if patients with cT1-T3a/bN0 rectal cancer can be treated with induction chemotherapy (FOLFOX/CAPOX) and organ-preserving surgery. Methods: Patients with MRI staged cT1-3a/bN0 tumors and no pathologic (p) high risk features received 6/4 cycles of FOLFOX/CAPOX, repeat sigmoidoscopy/pelvic MRI and subsequent Transanal Endoscopic Surgery (TES) in the absence of tumor progression. ypT0/T1N0 tumors were treated with observation while ypT2+ or ypN+ stage were recommended Total Mesorectal Excision (TME). The primary endpoint was protocol specified Organ Preservation Rate (psOPR = ypT0/T1N0, no p high risk features) and actual Organ Preservation Rate (aOPR = ypT0/T1N0 stage plus higher yp stage patients who declined TME surgery). The study would be considered negative with an psOPR of 50% or lower (H0) and as promising if it is 65% or higher (H1). Results: Between 08/2017 to 05/2020, 58 eligible patients were accrued in Canada and the United States, median age was 67 years, 71% male. All had well-moderately differentiated, non-mucinous rectal adenocarcinoma and median tumor height was 6 cm (range 0-18). Median follow-up was 15.4 months. Chemotherapy with FOLFOX (32) or CAPOX (26) was administered, 90% completed all planned cycles. A total of 56/58 (97%) proceeded to TES, while one patient was ineligible due to tumor progression (1.7%) and one declined. In the intention to treat analysis, the psOPR was 57% (95% CI 43-70%) while the aOPR was 79% (95% CI 67% to 89%) due to 13/23 declining recommended TME surgery. Of 10 patients who proceeded to recommended TME, a complete R0 TME was performed in 9/10, and no p residual carcinoma was found in 7/10. Crude loco-regional (LR) and distant recurrence rates were 3.5% (95% CI 0.4 to 12%) and 0%, respectively. A recurrence occurred in 1/13 patients who initially declined TME surgery. Conclusions: In select patients with early stage rectal cancer, three months of induction CAPOX/FOLFOX followed by TES resulted in a high OPR without the use of pelvic irradiation. The observed high rate of pathologic downstaging may point to high chemo-responsiveness in early rectal adenocarcinoma with no p high risk features. Further trials to evaluate this approach are justified and updated results will be presented. Clinical trial information: NCT03259035. [Table: see text]

scholarly journals Bladder and sexual dysfunction following laparoscopic and open mesorectal excision for rectal cancer

2011 ◽  
Vol 1 (1) ◽  
pp. 4
Author(s):  
Muhammad Shafique Sajid ◽  
Zishan Haider ◽  
Mohammed Rafay Siddiqui ◽  
Mirza Khurrum Baig
Keyword(s):  
Rectal Cancer ◽  
Sexual Dysfunction ◽  
Female Sexual Dysfunction ◽  
Bladder Dysfunction ◽  
Mesorectal Excision ◽  
Random Effects Models ◽  
Randomized Controlled ◽  
Fixed And Random Effects ◽  
Ejaculatory Dysfunction ◽  
Male Erectile Dysfunction

The objective of this review is to analyze the bladder and sexual dysfunction after laparoscopic (LTME) and open total mesorectal excision (OTME) for rectal cancer. Electronic databases were searched to find relevant randomized controlled trials and their data were analyzed to generate a summative outcome. Three studies on LTME and OTME encompassing 258 patients were retrieved from the electronic databases. Two studies on 108 patients qualified for this review. There were 53 and 55 patients in LTME and OTME groups respectively. In the both fixed and random effects models, statistically there was no difference in bladder dysfunction, overall sexual dysfunction, overall male sexual dysfunction, overall female sexual dysfunction, male erectile dysfunction and male ejaculatory dysfunction between LTME and OTME. Both LTME and OTME are associated with equal risk of bladder and sexual dysfunction in both genders following resections for rectal cancer.

Urinary and sexual dysfunction after rectal cancer treatment

2010 ◽  
Vol 8 (1) ◽  
pp. 51-57 ◽  
Author(s):  
Marilyne M. Lange ◽  
Cornelis J. H. van de Velde
Keyword(s):  
Rectal Cancer ◽  
Sexual Dysfunction ◽  
Cancer Treatment ◽  
Rectal Cancer Treatment

Contact x-ray brachytherapy 50 kV (CXB) for organ preservation in T2 T3a-b rectal cancer: Lyon-Nice experience in 120 patients.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 676-676
Author(s):  
Jerome Doyen ◽  
Eric Francois ◽  
Anne-Claire Frin ◽  
Karen Benezery ◽  
Fuxiang Zhou ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Organ Preservation ◽  
External Beam Radiotherapy ◽  
Rectal Adenocarcinoma ◽  
Bowel Function ◽  
Complete Response ◽  
Local Relapse ◽  
Concurrent Chemotherapy ◽  
High Rate ◽  
X Ray

676 Background: Organ preservation (avoiding TME surgery) for T2 T3 a-b rectal cancer is a field of active clinical research. Contact X Ray CXB combined with external beam radiotherapy (EBRT) ± concurrent chemotherapy (CRT) is an attractive method to achieve clinical complete response (cCR) and consequently rectal preservation. We report an overview of 120 patients treated with CXB+EBRT over a 25 year period in Lyon since 1986 and then in Nice until 2012. Methods: Between 1986 and 2012, 120 patients presenting rectal adenocarcinoma T2 T3a-b (distal rectum: 87; middle rectum: 33) were treated with CXB +EBRT with conservative intent. In Lyon (1986-2001), 80 patients median age: 73y; T2:52; T3:28) risk were treated using CXB (80-110 Gy/3-4 fr/4-6 weeks) followed by EBRT (39 Gy/13 fr/18 days) and 192 Iridium implant boost (20 Gy). When cCR was achieved, close surveillance was proposed. In Nice (2002-2012), 40 patients (median age 81y; T2:22; T3:18) received CXB same regimen as in Lyon (using new Papillon 50 machine since 2009) + EBRT (45-50 Gy/5weeks) with concurrent chemotherapy (5-FU or Capecitabine). When cCR was achieved close surveillance was proposed or local excision (13 pts). Results: Median follow-up time 58 months in both groups. Local relapse occurred mainly in the 2 first years. Isolated lymph node recurrence <5%. Bowel function good or excellent when rectum preserved. Main clinical outcomes in table (some improved results in Nice possibly due to better treatment approach and patient selection). Conclusions: CXB with EBRT and concurrent capecitabine achieve safely high rate of cCR with organ preservation. The OPERA randomized trial will reproduce Lyon R 96 trial (Gerard JP, JCO 2004;22:2404) and test the superiority of CXB boost for organ preservation. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document